ZVSA
ZyVersa Therapeutics, Inc.
Price Chart
Latest Quote
$0.17
Current Price| Previous Close | $0.16 |
| Open | $0.16 |
| Day High | $0.17 |
| Day Low | $0.16 |
| Volume | 225 |
Stock Information
| Shares Outstanding | 8.10M |
| Cash Equivalents | $528K |
| Net Income | $-25.70M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.38M |
| EPS (TTM) | $-3.32 |
| Exchange | OQB |
đ Custom Metrics & Score
Score: 10/42| Debt to Equity | 0.00 |
| Debt to Earnings | -0.00 |
| Current Ratio | 0.15 |
| Quick Ratio | 0.14 |
| Return on Equity | -110.53% |
| Avg FCF Growth | 12.23% |
| FCF Yield | -549.27% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $0.17 | 15 |
| 2026-01-30 | $0.16 | 8,700 |
| 2026-01-29 | $0.17 | 10,300 |
| 2026-01-28 | $0.18 | 7,100 |
| 2026-01-27 | $0.18 | 68,800 |
| 2026-01-26 | $0.19 | 13,100 |
| 2026-01-23 | $0.19 | 37,600 |
| 2026-01-22 | $0.18 | 1,600 |
| 2026-01-21 | $0.17 | 12,400 |
| 2026-01-20 | $0.20 | 4,400 |
| 2026-01-16 | $0.20 | 22,500 |
| 2026-01-15 | $0.17 | 98,700 |
| 2026-01-14 | $0.19 | 27,600 |
| 2026-01-13 | $0.19 | 62,500 |
| 2026-01-12 | $0.23 | 452,300 |
| 2026-01-09 | $0.26 | 1,507,800 |
| 2026-01-08 | $0.16 | 294,000 |
| 2026-01-07 | $0.15 | 307,700 |
| 2026-01-06 | $0.13 | 7,400 |
| 2026-01-05 | $0.13 | 182,200 |
About ZyVersa Therapeutics, Inc.
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $9,136,834 | $14,420,774 | $13,013,064 | $7,704,376 |
| Net Non Operating Interest Income Expense | $-269,856 | $457 | $-427,542 | $-821,366 |
| Total Other Finance Cost | $269,856 | $-457 | - | - |
| Operating Expense | $9,136,834 | $14,420,774 | $13,013,064 | $7,704,376 |
| General And Administrative Expense | $7,357,559 | $11,213,201 | $7,605,205 | $5,580,099 |
| Other Income Expense | - | $-93,333,459 | $-607,001 | $441,581 |
| Interest Expense | - | - | $427,542 | $821,366 |
| Interest Expense Non Operating | - | - | $427,542 | $821,366 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-9,413,435 | $-98,297,946 | $-14,047,607 | $-8,084,161 |
| Net Interest Income | $-269,856 | $457 | $-427,542 | $-821,366 |
| Normalized Income | $-9,413,435 | $-13,154,876 | $-13,440,606 | $-8,525,742 |
| Net Income From Continuing And Discontinued Operation | $-9,413,435 | $-98,297,946 | $-14,047,607 | $-8,084,161 |
| Total Operating Income As Reported | $-9,136,834 | $-107,754,233 | $-13,013,064 | $-7,704,376 |
| Net Income Common Stockholders | $-9,413,435 | $-106,246,155 | $-24,063,444 | $-8,084,161 |
| Net Income | $-9,413,435 | $-98,297,946 | $-14,047,607 | $-8,084,161 |
| Net Income Including Noncontrolling Interests | $-9,413,435 | $-98,297,946 | $-14,047,607 | $-8,084,161 |
| Net Income Continuous Operations | $-9,413,435 | $-98,297,946 | $-14,047,607 | $-8,084,161 |
| Pretax Income | $-9,406,690 | $-107,753,776 | $-14,047,607 | $-8,084,161 |
| Special Income Charges | $0 | $-93,333,459 | $0 | $213,481 |
| Operating Income | $-9,136,834 | $-14,420,774 | $-13,013,064 | $-7,704,376 |
| Interest Income | - | $457 | - | - |
| Interest Income Non Operating | - | $457 | - | - |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-8.48 | $-1089.70 | $-346.50 | $-139.88 |
| Basic EPS | $-8.48 | $-1089.70 | $-346.50 | $-139.88 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $-8,190,389 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-9,129,901 | $78,923,085 | $-13,003,196 | $-7,693,976 |
| Total Unusual Items | $0 | $-93,333,459 | $-607,001 | $441,581 |
| Total Unusual Items Excluding Goodwill | $0 | $-93,333,459 | $-607,001 | $441,581 |
| Reconciled Depreciation | $6,933 | $10,400 | $9,868 | $10,400 |
| EBITDA (Bullshit earnings) | $-9,129,901 | $-14,410,374 | $-13,610,197 | $-7,252,395 |
| EBIT | $-9,136,834 | $-14,420,774 | $-13,620,065 | $-7,262,795 |
| Diluted Average Shares | $1,110,033 | $97,500 | $69,126 | $57,792 |
| Basic Average Shares | $1,110,033 | $97,500 | $69,126 | $57,792 |
| Diluted NI Availto Com Stockholders | $-9,413,435 | $-106,246,155 | $-24,063,444 | $-8,084,161 |
| Tax Provision | $6,745 | $-9,455,830 | $0 | $0 |
| Write Off | $0 | $81,438,426 | $0 | - |
| Impairment Of Capital Assets | $0 | $11,895,033 | $0 | - |
| Research And Development | $1,779,275 | $3,207,573 | $5,407,859 | $2,124,277 |
| Selling General And Administration | $7,357,559 | $11,213,201 | $7,605,205 | $5,580,099 |
| Other Gand A | $7,357,559 | $11,213,201 | $7,605,205 | $5,580,099 |
| Preferred Stock Dividends | - | $7,948,209 | $10,015,837 | - |
| Gain On Sale Of Security | - | - | $-607,001 | $228,100 |
| Other Special Charges | - | - | - | $-213,481 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-10,131,456 | $-7,573,305 | $-11,987,034 | $-12,500,135 |
| Total Assets | $20,599,414 | $22,114,284 | $118,506,271 | $1,126,174 |
| Total Non Current Assets | $18,883,617 | $18,761,151 | $112,143,725 | $314,392 |
| Non Current Prepaid Assets | $178,476 | $98,476 | $46,659 | $286,659 |
| Non Current Deferred Assets | $57,238 | $0 | - | - |
| Goodwill And Other Intangible Assets | $18,647,903 | $18,647,903 | $111,981,362 | $0 |
| Other Intangible Assets | $18,647,903 | $18,647,903 | $100,086,329 | - |
| Current Assets | $1,715,797 | $3,353,133 | $6,362,546 | $811,782 |
| Other Current Assets | $184,873 | $215,459 | $225,347 | $106,929 |
| Cash Cash Equivalents And Short Term Investments | $1,530,924 | $3,137,674 | $5,902,199 | $328,581 |
| Cash And Cash Equivalents | $1,530,924 | $3,137,674 | $5,902,199 | $328,581 |
| Cash Financial | $1,530,924 | $3,137,674 | $5,902,199 | $328,581 |
| Prepaid Assets | - | $0 | $235,000 | $376,272 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $0 | $8,656 | $108,756 | $9,151,508 |
| Current Debt And Capital Lease Obligation | - | $8,656 | $108,756 | $9,151,508 |
| Net Debt | - | - | - | $8,822,927 |
| Current Debt | - | - | - | $9,151,508 |
| Other Current Borrowings | - | - | - | $9,151,508 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $12,082,967 | $11,039,686 | $18,511,943 | $13,626,309 |
| Total Non Current Liabilities Net Minority Interest | $851,659 | $844,914 | $10,323,983 | $0 |
| Non Current Deferred Liabilities | $851,659 | $844,914 | $10,323,983 | $0 |
| Non Current Deferred Taxes Liabilities | $851,659 | $844,914 | $10,323,983 | $0 |
| Current Liabilities | $11,231,308 | $10,194,772 | $8,187,960 | $13,626,309 |
| Other Current Liabilities | $7,261 | $507,261 | $1,148,421 | $1,709,021 |
| Payables And Accrued Expenses | $11,224,047 | $9,678,855 | $6,930,783 | $2,748,867 |
| Payables | $9,337,267 | $8,431,583 | $6,132,328 | $2,000,100 |
| Accounts Payable | $9,337,267 | $8,431,583 | $6,025,645 | $2,000,100 |
| Total Tax Payable | - | $0 | $106,683 | $0 |
| Income Tax Payable | - | $0 | $106,683 | $0 |
| Current Deferred Liabilities | - | - | $0 | $16,913 |
| Interest Payable | - | - | $0 | $748,767 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $8,516,446 | $11,074,597 | $99,994,326 | $-12,500,135 |
| Preferred Stock Equity | $1 | $1 | $2 | - |
| Total Equity Gross Minority Interest | $8,516,447 | $11,074,598 | $99,994,328 | $-12,500,135 |
| Stockholders Equity | $8,516,447 | $11,074,598 | $99,994,328 | $-12,500,135 |
| Retained Earnings | $-112,632,559 | $-103,219,124 | $-4,921,178 | $-52,896,817 |
| Other Equity Interest | - | - | $331,331 | $331,331 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $7 | $6 | - | - |
| Ordinary Shares Number | $2,508,191 | $405,205 | $25,948 | $25,948 |
| Share Issued | $2,508,198 | $405,211 | $25,948 | $25,948 |
| Tangible Book Value | $-10,131,457 | $-7,573,306 | $-11,987,036 | $-12,500,135 |
| Invested Capital | $8,516,446 | $11,074,597 | $99,994,326 | $-3,348,627 |
| Working Capital | $-9,515,511 | $-6,841,639 | $-1,825,414 | $-12,814,527 |
| Capital Lease Obligations | $0 | $8,656 | $108,756 | $0 |
| Total Capitalization | $8,516,447 | $11,074,598 | $99,994,328 | $-12,500,135 |
| Treasury Stock | $7,168 | $7,168 | $0 | - |
| Additional Paid In Capital | $121,155,922 | $114,300,849 | $104,584,147 | $40,065,109 |
| Capital Stock | $252 | $41 | $28 | $242 |
| Common Stock | $251 | $40 | $26 | $242 |
| Preferred Stock | $1 | $1 | $2 | $0 |
| Current Capital Lease Obligation | $0 | $8,656 | $108,756 | $0 |
| Current Accrued Expenses | $1,886,780 | $1,247,272 | $798,455 | $748,767 |
| Net PPE | $0 | $14,772 | $115,704 | $27,733 |
| Accumulated Depreciation | $-52,000 | $-45,067 | $-34,667 | $-24,267 |
| Gross PPE | $52,000 | $59,839 | $150,371 | $52,000 |
| Other Properties | $52,000 | $59,839 | $150,371 | $52,000 |
| Goodwill | - | $0 | $11,895,033 | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-7,559,697 | $-8,720,819 | $-1,494,641 | $-5,076,089 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-7,559,697 | $-8,720,819 | $-1,494,641 | $-5,076,089 |
| Cash Flow From Continuing Operating Activities | $-7,559,697 | $-8,720,819 | $-1,494,641 | $-5,076,089 |
| Operating Gains Losses | - | - | $607,001 | $-441,581 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $0 | $-10,702,779 | $0 | - |
| Issuance Of Capital Stock | $0 | $18,114,193 | $1,964,524 | $0 |
| Financing Cash Flow | $5,952,947 | $5,956,294 | $1,865,384 | $5,230,000 |
| Cash Flow From Continuing Financing Activities | $5,952,947 | $5,956,294 | $1,865,384 | $5,230,000 |
| Net Other Financing Charges | $-588,045 | $-2,422,595 | $-99,140 | - |
| Net Preferred Stock Issuance | $0 | $-10,695,611 | $1,964,524 | $0 |
| Net Common Stock Issuance | $0 | $18,107,025 | $0 | $0 |
| Common Stock Issuance | $0 | $18,114,193 | $0 | $0 |
| Preferred Stock Issuance | - | $0 | $1,964,524 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| End Cash Position | $1,530,924 | $3,137,674 | $699,324 | $328,581 |
| Beginning Cash Position | $3,137,674 | $5,902,199 | $328,581 | $174,670 |
| Changes In Cash | $-1,606,750 | $-2,764,525 | $370,743 | $153,911 |
| Proceeds From Stock Option Exercised | $6,540,992 | $967,475 | $0 | $0 |
| Preferred Stock Payments | $0 | $-10,695,611 | $0 | - |
| Common Stock Payments | $0 | $-7,168 | $0 | - |
| Change In Working Capital | $929,884 | $2,600,444 | $8,291,886 | $-1,020,316 |
| Change In Other Working Capital | $97,877 | - | - | - |
| Change In Other Current Liabilities | $-8,656 | $-100,100 | $-86,100 | $0 |
| Change In Payables And Accrued Expense | $890,077 | $2,507,473 | $8,048,684 | $-723,220 |
| Change In Accrued Expense | $139,508 | $101,535 | $1,431,620 | $-411,358 |
| Change In Payable | $750,569 | $2,405,938 | $6,617,064 | $-311,862 |
| Change In Account Payable | $750,569 | $2,405,938 | $6,617,064 | $-311,862 |
| Change In Prepaid Assets | $-49,414 | $193,071 | $329,302 | $-297,096 |
| Other Non Cash Items | $204,609 | $1,918,930 | $119,410 | $317,833 |
| Stock Based Compensation | $705,567 | $1,192,963 | $3,524,801 | $4,141,736 |
| Asset Impairment Charge | $0 | $93,333,459 | $0 | - |
| Deferred Tax | $6,745 | $-9,479,069 | $0 | $0 |
| Deferred Income Tax | $6,745 | $-9,479,069 | $0 | $0 |
| Depreciation Amortization Depletion | $6,933 | $10,400 | $9,868 | $10,400 |
| Depreciation And Amortization | $6,933 | $10,400 | $9,868 | $10,400 |
| Depreciation | $6,933 | $10,400 | $9,868 | $10,400 |
| Net Income From Continuing Operations | $-9,413,435 | $-98,297,946 | $-14,047,607 | $-8,084,161 |
| Issuance Of Debt | - | - | $0 | $5,230,000 |
| Net Issuance Payments Of Debt | - | - | $0 | $5,230,000 |
| Net Short Term Debt Issuance | - | - | $0 | $5,230,000 |
| Short Term Debt Issuance | - | - | $0 | $5,230,000 |
| Gain Loss On Investment Securities | - | - | $607,001 | $-228,100 |
| Net Long Term Debt Issuance | - | - | - | $5,230,000 |
| Long Term Debt Issuance | - | - | - | $5,230,000 |
| Gain Loss On Sale Of PPE | - | - | - | $-213,481 |